PHARMACOKINETICS OF HALOFANTRINE IN THAI PATIENTS WITH ACUTE UNCOMPLICATED FALCIPARUM-MALARIA

被引:42
作者
KARBWANG, J
MILTON, KA
BANGCHANG, KN
WARD, SA
EDWARDS, G
BUNNAG, D
机构
[1] UNIV LIVERPOOL,SCH TROP MED,DEPT PHARMACOL & THERAPEUT,LIVERPOOL L69 3BX,ENGLAND
[2] UNIV LIVERPOOL,SCH TROP MED,DEPT PARASITOL,LIVERPOOL L69 3BX,ENGLAND
[3] MAHIDOL UNIV,HOSP TROP DIS,FAC TROP MED,BANGKOK 10700,THAILAND
[4] MAHIDOL UNIV,DEPT CLIN TROP MED,CLIN PHARMACOL UNIT,BANGKOK 10700,THAILAND
基金
英国惠康基金;
关键词
HALOFANTRINE; ANTIMALARIAL; PHARMACOKINETICS;
D O I
10.1111/j.1365-2125.1991.tb05567.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Twelve patients with acute uncomplicated falciparum malaria were admitted to the Hospital for Tropical Diseases for 42 days. The patients were treated with halofantrine 500 mg 6 hourly for three doses and halofantrine and its desbutyl metabolite were analysed in plasma by h.p.l.c. C(max) values of halofantrine and desbutylhalofantrine (n = 12) were 1192 +/- 410 (mean +/- s.d.) and 397 +/- 160 ng ml-1 with t(max) values of 16 +/- 2 and 55 +/- 26 h, respectively. AUC was 60.6 +/- 23.9 and 48.5 +/- 22.2 mg l-1 h, respectively, for halofantrine and its metabolite. Halofantrine cured 83% of the patients but in two patients a reduction only in asexual parasitaemia was seen and no overall parasite clearance occurred. One of these, however had relatively low plasma concentrations of both halofantrine and its desbutyl metabolite and it appeared to be a case of inadequate treatment rather than true resistance. We suggest that the large intersubject variability in plasma drug concentrations may relate in part to its poor and inconsistent bioavailability and this rather than true resistance might be responsible for some of the treatment failures.
引用
收藏
页码:484 / 487
页数:4
相关论文
共 16 条
[1]  
BOUDREAU EF, 1988, B WORLD HEALTH ORGAN, V66, P227
[2]  
BROOM C, 1989, PARASITOL TODAY, P15
[3]  
BRUCECHWATT LJ, 1980, ESSENTIAL MALARIOLOG, P196
[4]  
COSGRIFF TM, 1982, AM J TROP MED HYG, V31, P227
[5]   TREATMENT OF IMPORTED CASES OF FALCIPARUM-MALARIA IN FRANCE WITH HALOFANTRINE [J].
COULAUD, JP ;
LEBRAS, J ;
MATHERON, S ;
MORINIERE, B ;
SAIMOT, AG ;
ROSSIGNOL, JF .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1986, 80 (04) :615-616
[6]  
DESJARDINS RE, 1979, ANTIMICROBIAL AGENTS, V23, P292
[7]  
FLECKENSTEIN L, 1983, 2ND INT C MAL BAB AN, P87
[8]  
Gibaldi M, 1982, PHARMACOKINETICS, P494
[9]   INTRODUCTION OF HALOFANTRINE FOR MALARIA TREATMENT [J].
HORTON, RJ .
PARASITOLOGY TODAY, 1988, 4 (09) :238-239
[10]   A COMPARISON OF THE PHARMACOKINETICS OF MEFLOQUINE IN HEALTHY THAI VOLUNTEERS AND IN THAI PATIENTS WITH FALCIPARUM-MALARIA [J].
KARBWANG, J ;
BACK, DJ ;
BUNNAG, D ;
BRECKENRIDGE, AM .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 35 (06) :677-680